secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007655
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair
--------------------------------------------------------------------------------

- Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.
- Cheryl Blanchard transitions from CEO to Executive Chair for 12 months, then Special Advisor.
- Reaffirmed FY2025 guidance: Commercial Channel $47-49.5M (+12-18% YoY), OEM $62-65M (-16-20% YoY).
- Director Susan Vogt resigns effective Feb 1, 2026; no disagreements with the Company.
- Griffin receives $690k base salary, 75% target bonus, and $2.45M equity grant vesting over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/0001193125-26-007655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000119312526007655/d136217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer